AMENDMENT No. 3 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT

Exhibit 10.71

AMENDMENT No. 3

TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT

This Amendment No. 3 to the Veto Cell Production and Clinical Trial Program Agreement (“Amendment”) is made and entered into as of May 1, 2023 by and between Cell Source Limited (“Cell Source”) and The University of Texas X.X. Xxxxxxxx Cancer Center (“MD Xxxxxxxx”), a member institution of The University of Texas System (“System”).

RECITALS

A. Cell Source and MD Xxxxxxxx entered into a Veto Cell Production and Clinical Trial Program Agreement dated February 19, 2019 (the “Agreement”).

B. Cell Source and MD Xxxxxxxx wish to amend the terms of the Agreement as set forth below.

NOW, THEREFORE, it is hereby agreed as follows:

1. Exhibit B of the Agreement shall be extended (after completion of the treatment of the first 12 patients) with the attached Amended Exhibit B, which will cover the second set of 12 patients currently planned in the clinical trial.

2. Except as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall continue in full force and effect as provided therein.

IN WITNESS WHEREOF, Cell Source and MD Xxxxxxxx have entered into this Amendment effective as of the date first set forth above.

CELL SOURCE			THE UNIVERSITY OF TEXAS
			X.X. XXXXXXXX CANCER CENTER
By			By
	Xxxxxx Xxxxxxx		Name
	Chief Executive Officer		Title
Date:			Date:
			Read & Understood:
			Xx. Xxxxxxx Xxxxxxxx
			Principal Investigator

PAYMENT SCHEDULE:

Milestone		Payment*
Upon enrollment of 3 subjects (total 3/12 subjects)		$	107,728.55
Upon enrollment of 3 subjects (total 6/12 subjects)		$	107,728.55
Upon enrollment of 3 subjects (total 9/12 subjects)		$	107,728.55
Upon enrollment of 3 subjects (total 12/12 subjects)		$	107,728.55

Payments for Invoicable items: The following are per patient costs per fiscal year.

* Upon anniversary of the execution of this contract Department and IND maintenance fees are invoiced . Other fees are invoiced as they occur.

Amended Exhibit B

Budget